Produção Nacional
Revisado por pares
Cytoplasmic CCR7 (CCR7c) immunoexpression is associated with local tumor recurrence in triple-negative breast cancer
2020; Elsevier BV; Volume: 216; Issue: 12 Linguagem: Inglês
10.1016/j.prp.2020.153265
ISSN1618-0631
AutoresDaniel Cordeiro Gurgel, Deysi Viviana Tenazoa Wong, Alessandro Maia Bandeira, Jorge Fernando Bessa Pereira, Jedson Vieira Gomes-Filho, Ana Carolina Pereira, Paulo Goberlanio Barros Silva, Fabio Távora, Anamaria Falcão Pereira, Roberto César Pereira Lima‐Júnior, Paulo Roberto Carvalho de Almeida,
Tópico(s)Cell Adhesion Molecules Research
ResumoTriple-negative breast cancer (TNBC) is a subtype of cancer, which tests negative for estrogen receptors, progesterone receptors, and lacks overexpression of the human epidermal growth factor 2 (C-erbB2, HER2/neu) gene. The expression of chemokines and their receptors, including CCR7, has been described in several types of cancer, contributing to tumor progression. This study investigated the association between the membrane and cytoplasmic CCR7 expression and the prognosis of TNBC. Surgical paraffin histopathology blocks and clinico-pathological data were assessed from 133 patients. Samples were analyzed by immunohistochemistry and immunofluorescence using the Tissue Microarray technique for scoring the intensity of CCR7 expression. TNBC patients in which the CCR7 labeling was predominantly in the cytoplasm of tumor cells presented increased local tumor recurrence (P = 0.033). Conversely, there was no statistical difference in five-year overall survival between the patients with low (77%) versus high (80%) cytoplasmic CCR7 expression (P = 0.7104). Additionally, the risk of death between these groups was 1.19 (95% CI = 0.48–2.91). The cytoplasmic CCR7 expression associates with an increased incidence of tumor relapse in TNBC, not affecting patients survival. Consequently, the cell compartment in which the CCR7 localizes could serve as a prognostic marker in this cancer subtype.
Referência(s)